Researchers Identify Multi-Action Drug Candidate For Type 2 Diabetes And Bone Disease Posted on: July 28, 2016 in News | Life Science News | Pharma News By: Sarah Massey, M.Sc. Share this: Click to share on LinkedIn (Opens in new window) LinkedIn Click to share on Facebook (Opens in new window) Facebook Click to share on X (Opens in new window) X Click to share on Reddit (Opens in new window) Reddit Click to email a link to a friend (Opens in new window) Email Subscribe Related Vitals J&J’s Icotyde (Icotrokinra) Receives FDA Nod as First Oral Biologic for Plaque Psoriasis News March 31, 2026 UCB Invests $2B in New Biologics Manufacturing Site in Georgia News March 31, 2026 Lifyorli (Relacorilant) Combo FDA-Approved for Platinum-Resistant Ovarian Cancer News March 31, 2026 Kresladi Receives FDA Nod as First Gene Therapy for Rare Genetic Immune Disorder News March 30, 2026 Novo Nordisk’s Awiqli Wins FDA Approval as First Once-Weekly Insulin News March 30, 2026 Related Webinars May 20, 2026 Using AI to Accelerate Clinical Trials Under Regulatory Scrutiny May 06, 2026 MRD-Driven Oncology Trials: Regulatory, Clinical and Pharmacology Considerations May 20, 2026 Measuring What Matters in ALS: The ALSFRS-R April 23, 2026 Inclusive Research Starts Locally: Improving Trial Readiness Through Community‑Based Models May 13, 2026 Neuroscience Drug Development: How Novel Applications of AI Could Meaningfully Disrupt Traditional Development Strategies Join or login to leave a comment JOIN LOGIN Subscribe to our newsletters Not a member yet? Sign up for our newsletters and receive webinars, vitals, and updates for your topic of choice Preferences Xtalks Vitals Vitals Life Science Vitals Food Industry Vitals Medical Devices Marketing Insights Blog First Name*Last Name*Country*Email* CAPTCHA
Join or login to leave a comment
JOIN LOGIN